CIBICI   14215
CENTRO DE INVESTIGACION EN BIOQUIMICA CLINICA E INMUNOLOGIA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
A NOVEL THERAPEUTIC TARGET FOR TREATING NEURODEGENERATION AND VASCULAR PERMEABILITY IN DIABETIC RETINOPATHY.
Autor/es:
SARAGOVI HU; JMAEFF S; GALAN A; ESQUIVA G; CUENCA N; BARCELONA PF
Lugar:
Denver
Reunión:
Congreso; ARVO 2015 Annual Meeting (The Association for Research in Vision and Ophthalmology).; 2015
Institución organizadora:
The Association for Research in Vision and Ophthalmology.
Resumen:
Propose: The p75NTR is a neurotrophin receptor promotes neuronal pruning and death, and recently was implicated in cardiovascular disorders. In the healthy adult retina p75NTR and proNGF are expressed at very low levels, but are up regulated in many disease state (e.g. Muller cells during glaucoma and retinitis pigmentosa, and neovasculature during retinopathy of prematury). For that reason, we studied p75NTR in vascular and the neurodegenerative pathologies associated with Diabetic Retinipathy. Methods: We have used drug-like pharmacological antagonists of p75NTR or biological antagonists of proNGF (neutralizing anti-proNGF mAb), administered after disease onset. We studied the mechanism of action of p75NTR and its role in diabetes pathology, and modulation of the pathology by the inhibitors in the Streptozotocin (STZ) animals models. Drug delivery was by 1x intravitreal injection after disease onset. Endpoints: FD-OCT quantification of retinal structure, biochemical quantification of p75NTR signals, kinetics of expression of receptor and ligand during disease progression by immunofluorescence and biochemical analyses, and neuronal survival was quantified by TUNEL assay and by counting BRN3 labeled cells in whole retina. Vascular permeability and leakage is quantified by Evans Blue extravasation. Time-dependent kinetic studies were done from 1 week to 6 weeks of diabetes. Results: We have shown that p75NTR is up-regulated in Muller glial cells, and it is responsible for promoting glial production of neurotoxic cytokines TNF-α and α2M, which in turn kill RGCs. As well p75NTR is up-regulated in vasculature causing vascular dysfunction. The kinetics of p75NTR expression correlate with the disiease progression. Pharmacological inhibition of p75NTR or of the proNGF ligand normalizes levels of neurotoxic cytokines and prevents neuronal fiber loss, prevents RGC death and reduces vascular permeability. Conclusion: The p75NTR mechanisms are paracrine by regulation of glia and vascular biology, impacting on RGC health and vascular permeability. Using p75NTR antagonists or proNGF antagonists, it was possible to ameliorate the neuronal component as well as the vascular component of the pathology in diabetes. These studies validate p75NTR as a druggable therapeutic target for diabetic retinipathy; and potentially it could be a target for other diseases.